文献速递肿瘤 PET/CT

阐明免疫PET-CT在非小细胞肺癌中的作用:临床价值与研究趋势

Demystifying the Role of Immuno PET-CT in Non-Small Cell Lung Cancer: Clinical Value and Research Trends.
PubMed 文献 · Semin Nucl Med · 2025-02-27

本文综述了靶向PD1和PDL1的免疫PET示踪剂在非小细胞肺癌分子表征中的最新证据,总结了其对标准治疗耐药、考虑免疫治疗等额外干预患者的临床价值,并梳理了该领域的研究趋势。

要点

  • 靶向PD1/PDL1的免疫PET用于非小细胞肺癌分子表征。
  • 适用人群为对标准治疗耐药、考虑免疫治疗等干预者。
  • 本文汇总该领域最新证据并综述研究趋势。

核心结论

  • 靶向PD1和PDL1的免疫PET示踪剂正越来越多用于对标准治疗耐药、考虑免疫治疗等额外干预患者的分子表征。

研究设计与样本

  • 本文为综述,汇总免疫PET-CT在非小细胞肺癌中的最新证据并综述研究趋势。

主要发现

  • 靶向程序性细胞死亡相关靶点如PD1和PDL1的示踪剂(统称免疫PET)正越来越多用于分子表征。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The management of Lung cancer, especially non-small cell lung cancer has undergone a paradigm shift recently with the advent of new treatment approaches including focused radiotherapy as well as evolution of a newer class of immunotherapy agents. Treatment efficacy and survival rates have improved and it is now even more important that patients are selected for appropriate interventions on the basis of a comprehensive assessment including a range of imaging as well as in-vitro tests such as immunohistochemistry. A new class of tracers targeting programmed cell death such as PD1 and PDL1 (broadly classed as Immuno PET) are being increasingly used in the molecular characterisation of patients deemed resistant to standard treatment approaches and being considered for additional interventions such as immunotherapy. In this review, we review the latest evidence in the field and propose a summary of clinical usefulness and provide a review of the research trends in this exciting and evolving field.

来源:Semin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Vinjamuri S, Pant V. Demystifying the Role of Immuno PET-CT in Non-Small Cell Lung Cancer: Clinical Value and Research Trends. Semin Nucl Med. 2025. PMID: 40016063. doi:10.1053/j.semnuclmed.2025.02.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。